Log in to save to my catalogue

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through...

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1190b8e3606d4217ab6c491c95462033

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

About this item

Full title

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Publisher

United States: American Society for Clinical Investigation

Journal title

The Journal of clinical investigation, 2022-12, Vol.132 (23)

Language

English

Formats

Publication information

Publisher

United States: American Society for Clinical Investigation

More information

Scope and Contents

Contents

Testosterone is the canonical growth factor of prostate cancer but can paradoxically suppress its growth when present at supraphysiological levels. We have previously demonstrated that the cyclical administration of supraphysiological androgen (SPA), termed bipolar androgen therapy (BAT), can result in tumor regression and clinical benefit for pati...

Alternative Titles

Full title

Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_1190b8e3606d4217ab6c491c95462033

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1190b8e3606d4217ab6c491c95462033

Other Identifiers

ISSN

1558-8238,0021-9738

E-ISSN

1558-8238

DOI

10.1172/JCI162396

How to access this item